2019•Faculty Opinions – Post-Publication Peer Review of the Biomedical LiteratureRequires access

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Corrado Girmenia

Abstract

Read the full review for this Faculty Opinions recommended article: Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ofatumumab, Idelalisib, Medicine, Open label, Family medicine, Internal medicine, Ibrutinib, Oncology